Table 1.
AIA litigation related patents naming Michael Mullan as inventor and AIA as assignee. Note that all patents claimed the June 4, 1992 priority date.
| Patent number | Title | Subject matter | Filed/Published |
|---|---|---|---|
| US 5,455,169 | Nucleic acids for diagnosing and modeling Alzheimer's disease | Claims (1) the nucleic acid of the human APP with asparagine at codon 670 and/or leucine at codon 671, or a fragment of the protein; (2) a further specification about the amino acid at codon 717; (3) a vector that includes the nucleic acid; and (4) an immortalized mammalian cell line that contains the nucleic acid in question. | 1992-06-04/1995-10-03 |
| US 5,795,963 | APP in Alzheimer's disease | Claims the purified and isolated polypeptide of human APP that includes codons 670 and 671, where asparagine is at codon 670 and/or leucine is at codon 671. | 1997-03-13/1998-08-18 |
| US 6,818,448 | Isolated cell comprising HAPP 670/671 DNAS sequences | Claims (1) an isolated (and immortalized) cell with a nucleic acid encoding a human APP that includes codons 670 and 671, operable linked to a promoter. The nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. The cell expresses the human APP or a fragment of it; (2) the same claim that includes codon 717, with an amino acid other than valine; and (3) a method of screening for an agent for treating Alzheimer's disease that involves contacting the claimed cell with an agent and monitoring the expression or processing of APP or fragments thereof. | 2001-02-16/2004-11-16 |
| US 7,538,258 | Transgenic mouse expressing an APP 670/671 mutation | Claims (1a) a transgenic mouse whose genome comprises a nucleic acid encoding human APP including codons 670 and 671, operably linked to a promoter, where the amino acid at codon 670 is not lysine and/or the amino acid at 671 is not methionine and the mouse expresses this protein or a fragment of it; (b) a transgenic mouse that has an amino acid other than valine at codon 717; and (c) the mouse forms amyloidogenic aggregates in its brain and/or exhibits Alzheimer's disease pathology; and (2) a method of screening for an agent for treating Alzheimer's disease through contacting the mouse with an agent and monitoring the expression, processing or deposition of APP ,or fragments of it. | 2007-03-08/2009-05-26 |